Department of Oncology and Hemato-Oncology, Università degli Studi di Milano, Piazza Ospedale Maggiore, 3, 20162, Milan, Italy.
Department of Hematology, Oncology, and Molecular Medicine, Grande Ospedale Metropolitano Niguarda, Milan, Italy.
World J Surg Oncol. 2023 Mar 31;21(1):118. doi: 10.1186/s12957-023-02976-0.
Cancers of the Vater ampulla (ampullary cancers, ACs) account for less than 1% of all gastrointestinal tumors. ACs are usually diagnosed at advanced stage, with poor prognosis and limited therapeutic options. BRCA2 mutations are identified in up to 14% of ACs and, differently from other tumor types, therapeutic implications remain to be defined. Here, we report a clinical case of a metastatic AC patient in which the identification of a BRCA2 germline mutation drove a personalized multimodal approach with curative-intent.
A 42-year-old woman diagnosed with stage IV BRCA2 germline mutant AC underwent platinum-based first line treatment achieving major tumor response but also life-threatening toxicity. Based on this, as well as on molecular findings and expected low impact of available systemic treatment options, the patient underwent radical complete surgical resection of both primary tumor and metastatic lesions. Following an isolated retroperitoneal nodal recurrence, given the expected enhanced sensitivity to radiotherapy in BRCA2 mutant cancers, the patient underwent imaging-guided radiotherapy leading to long-lasting complete tumor remission. After more than 2 years, the disease remains radiologically and biochemically undetectable. The patient accessed a dedicated screening program for BRCA2 germline mutation carriers and underwent prophylactic bilateral oophorectomy.
Even considering the intrinsic limitations of a single clinical report, we suggest that the finding of BRCA germline mutations in ACs should be taken into consideration, together with other clinical variables, given their potential association with remarkable response to cytotoxic chemotherapy that might be burdened with enhanced toxicity. Accordingly, BRCA1/2 mutations might offer the opportunity of personalizing treatment beyond PARP inhibitors up to the choice of a multimodal approach with curative-intent.
壶腹癌(Vater 壶腹癌,AC)占所有胃肠道肿瘤的比例不到 1%。AC 通常在晚期诊断,预后差,治疗选择有限。高达 14%的 AC 中发现 BRCA2 突变,与其他肿瘤类型不同,其治疗意义仍有待确定。在这里,我们报告了一例转移性 AC 患者的临床病例,该患者的 BRCA2 种系突变的鉴定导致了有治愈意图的个性化多模式治疗。
一名 42 岁女性被诊断为 IV 期 BRCA2 种系突变 AC,接受铂类一线治疗后获得主要肿瘤反应,但也出现危及生命的毒性。基于此,以及分子发现和预期可用系统治疗方案的影响较低,患者接受了原发性肿瘤和转移性病变的根治性完全手术切除。在孤立性腹膜后淋巴结复发后,鉴于 BRCA2 突变癌症对放射治疗的预期增强敏感性,患者接受了影像学引导的放射治疗,导致长期完全肿瘤缓解。2 年多后,疾病在影像学和生物化学上仍无法检测到。患者参加了 BRCA2 种系突变携带者的专门筛查计划,并接受了预防性双侧卵巢切除术。
即使考虑到单个临床报告的固有局限性,我们建议在 AC 中发现 BRCA 种系突变应与其他临床变量一起考虑,因为它们可能与对细胞毒性化疗的显著反应相关,而这种反应可能伴随着增强的毒性。因此,BRCA1/2 突变可能提供了超越 PARP 抑制剂的个性化治疗机会,直至选择有治愈意图的多模式治疗。